CSA-131, A ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates

International Journal of Antimicrobial Agents

Volumn 46, Issue 5, 2015, Pages 568-571

  Vila Farrés, Xavier ^a,b   Callarisa, Anna Elena ^a   Gu, Xiaobo ^c   Savage, Paul B ^c   Giralt, Ernest ^a,b   Vila, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c Brigham Young University   (United States)

Author keywords

Acinetobacter baumannii; Activity; Ceragenins; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; CATIONIC STEROID COMPOUND; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CERAGENIN; CIPROFLOXACIN; COLISTIN; CSA 13; CSA 131; CSA 138; CSA 44; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN; RIFAMPICIN; STEROID; SULBACTAM; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; TIME FACTOR;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; STEROIDS; TIME FACTORS;

EID: 84947025110     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.08.003     Document Type: Article

References (15)

1. World Health Organization Antimicrobial resistance: global report on surveillance 2014 2014 WHO Geneva, Switzerland
2. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, and et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
3. J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, C.R. Rayner, and et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect Dis 6 2006 589 601
4. X. Vila-Farrés, E. Giralt, and J. Vila Update of peptides with antibacterial activity Curr Med Chem 19 2012 6188 6198
5. A.L. Hilchie, K. Wuerth, and R.E. Hancock Immune modulation by multifaceted cationic host defense (antimicrobial) peptides Nat Chem Biol 9 2013 761 768
6. C. Li, A.S. Peters, E.L. Meredith, G.W. Allman, and P.B. Savage Design and synthesis of potent sensitizers of Gram-negative bacteria based on a cholic acid scaffolding J Am Chem Soc 120 1998 2961 2962
7. Ç. Bozkurt-Güzel, M. Tüysüz, N. Inan, and P.B. Savage Investigation of the antifungal activities of the cationic steroid antibiotic CSA-8, CSA-13, CSA-44, CSA-131 and CSA-138 against Candida albicans isolated from blood cultures ANKEM Derg 28 2014 8 13 [in Turkish]
8. R. López-Rojas, M.J. McConnell, M.E. Jiménez-Mejías, J. Domínguez-Herrera, F. Fernández-Cuenca, and J. Pachón Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness Antimicrob Agents Chemother 57 2013 4587 4589
9. Clinical and Laboratory Standards Institute Performance standards for antimicrobial disk susceptibility tests; approved standard - ninth edition. Document M02-A9 2006 CLSI Wayne, PA
10. X-Z. Lai, Y. Feng, J. Pollard, J.N. Chin, M.J. Rybak, R. Bucki, and et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides Acc Chem Res 41 2008 1233 1240
11. J.N. Chin, M.J. Rybak, C.M. Cheung, and P.B. Savage Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus Antimicrob Agents Chemother 51 2007 1268 1273
12. R.F. Epand, P.B. Savage, and R.M. Epand Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (ceragenins) Biochim Biophys Acta 1768 2007 2500 2509
13. J.N. Chin, R.N. Jones, H.S. Sader, P.B. Savage, and M.J. Rybak Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P aeruginosa J Antimicrob Chemother 61 2008 365 370
14. C. Bozkurt-Guzel, P.B. Savage, A. Akcali, and B. Ozbek-Celik Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients Biomed Res Int 2014 2014 710273
15. J.E. Pollard, J. Snarr, V. Chaudhary, J.D. Jenning, H. Shaw, B. Christiansen, and et al. In vitro evaluation of the potential for resistance development to ceragenin CSA-13 J Antimicrob Chemother 67 2012 2665 2672